Data from BioTime’s OpRegen Program to Be Presented at AAO 2018

Source: BioTime

BioTime announced that its abstract “PI/IIa Study of Subretinally Transplanted Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry-Form AMD Patients,” has been accepted for an oral presentation at the upcoming American Academy of Ophthalmology (AAO) meeting taking place from October 27-30, 2018, in Chicago, Illinois.

“We are delighted that the AAO has accepted our abstract for an oral presentation at the upcoming meeting,” Adi Mohanty, Co-Chief Executive Officer of BioTime, said in a company news release. “We look forward to sharing more data from the ongoing OpRegen clinical trial where we have observed signals that may suggest structural improvement in the retina.”


Related Content